An adjusted ELISpot-based immunoassay for evaluation of SARS-CoV-2-specific T-cell responses

Like antibody evaluation, using an effective antigen-specific T-cell immunity assessment method in coronavirus disease 2019 (COVID-19) patients, survivors and vaccinees is crucial for understanding the immune persistence, prognosis assessment, and vaccine development for COVID-19. This study evaluat...

Full description

Saved in:
Bibliographic Details
Main Authors: Hao Lin (Author), Jie Zhang (Author), Shaobo Dong (Author), Yaning Liu (Author), Peipei Liu (Author), George F. Gao (Author), William J. Liu (Author), Guizhen Wu (Author)
Format: Book
Published: Elsevier, 2022-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8f33e33411a545d5a34e402c9b01d5c9
042 |a dc 
100 1 0 |a Hao Lin  |e author 
700 1 0 |a Jie Zhang  |e author 
700 1 0 |a Shaobo Dong  |e author 
700 1 0 |a Yaning Liu  |e author 
700 1 0 |a Peipei Liu  |e author 
700 1 0 |a George F. Gao  |e author 
700 1 0 |a William J. Liu  |e author 
700 1 0 |a Guizhen Wu  |e author 
245 0 0 |a An adjusted ELISpot-based immunoassay for evaluation of SARS-CoV-2-specific T-cell responses 
260 |b Elsevier,   |c 2022-06-01T00:00:00Z. 
500 |a 2590-0536 
500 |a 10.1016/j.bsheal.2022.04.005 
520 |a Like antibody evaluation, using an effective antigen-specific T-cell immunity assessment method in coronavirus disease 2019 (COVID-19) patients, survivors and vaccinees is crucial for understanding the immune persistence, prognosis assessment, and vaccine development for COVID-19. This study evaluated an empirically adjusted enzyme-linked immunospot assay for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T-cell immunity in 175 peripheral blood samples from COVID-19 convalescents and healthy individuals. Results of viral nucleic acid were used as the gold standard of infection confirmation. The SARS-CoV-2M peptide pool had higher sensitivity of 85% and specificity of 71% for the single peptide pool. For combined peptide pools, the parallel evaluation (at least one of the peptide pools is positive) of total peptide pools (S1&S2&M&N) had higher sensitivity (up to 93%), and the serial evaluation (all peptide pools are positive) of total peptide pools had higher specificity (up to 100%). The result of the serial evaluation was better than that of the parallel evaluation as a whole. The detection efficiency of M and N peptide pool serial evaluation appeared the highest, with a sensitivity of 80% and specificity of 93%. This T-cell immunity detection assay introduced in this report can achieve high operability and applicability. Therefore, it can be an effective SARS-CoV-2-specific cellular immune function evaluation method. 
546 |a EN 
690 |a SARS-CoV-2 
690 |a COVID-19 
690 |a T-cell response 
690 |a ELISpot assay 
690 |a Sensitivity 
690 |a Specificity 
690 |a Infectious and parasitic diseases 
690 |a RC109-216 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Biosafety and Health, Vol 4, Iss 3, Pp 179-185 (2022) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2590053622000532 
787 0 |n https://doaj.org/toc/2590-0536 
856 4 1 |u https://doaj.org/article/8f33e33411a545d5a34e402c9b01d5c9  |z Connect to this object online.